Drugs / Alpha1-PI
Alpha1-PI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02093221 | Mar 2014 → Jan 2017 | type 1 diabetes mellitus | Grifols Therapeutics LLC | Terminated | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha1-PI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02093221 ↗ |
| Known as | alpha1 -PI [human] | “Because alpha1 -PI [human] (alpha1 -PI[h]) therapy can inhibit pro-inflammatory mediators associated with β-cell destruction and reduced insulin production” PMID 33244872 ↗ Dec 2020 |
| Known as | alpha1 -PI[h] | “Because alpha1 -PI [human] (alpha1 -PI[h]) therapy can inhibit pro-inflammatory mediators associated with β-cell destruction and reduced insulin production” PMID 33244872 ↗ Dec 2020 |
| Action | Inhibit | “alpha1 -PI [human] (alpha1 -PI[h]) therapy can inhibit pro-inflammatory mediators associated with β-cell destruction and reduced insulin production” PMID 33244872 ↗ Dec 2020 |
| Modality | Protein / enzyme biologic | “Human plasma-derived alpha(1) -proteinase inhibitor” PMID 33244872 ↗ Dec 2020 |
| Route | Intravenous | “intravenous (IV) alpha1 -PI[h]” PMID 33244872 ↗ Dec 2020 |